Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals, Inc.'s Days of Sales Outstanding (DSO) is a financial metric that indicates the average number of days it takes for the company to collect revenue from its sales. A lower DSO is generally preferable as it suggests that the company is collecting revenue more quickly.

Analyzing the trend in Ligand Pharmaceuticals, Inc.'s DSO over the past five years reveals fluctuations in efficiency of receivables management.

In 2023, the DSO increased significantly to 109.27 days from 65.17 days in 2022, indicating a deterioration in the company's ability to collect revenue from sales promptly. This elongated collection period may be a cause for concern as it ties up working capital and may indicate difficulties in managing accounts receivable efficiently.

Comparing 2023 to 2021, the DSO decreased from 120.70 days to 109.27 days, showing an improvement in collecting sales revenue promptly. This reduction suggests enhanced effectiveness in managing receivables and potentially better cash flow management.

When comparing 2023 to 2019, there has been a notable reduction in DSO from 126.69 days to 109.27 days. This improvement signifies an enhanced ability to convert sales into cash quicker than in previous years, which could be beneficial for liquidity and working capital management.

Overall, while there has been variability in Ligand Pharmaceuticals, Inc.'s DSO over the years, the company should aim to maintain a lower DSO to ensure efficient cash flow and working capital management. Vigilant monitoring of accounts receivable processes and timely collection efforts could help enhance the company's financial performance in the future.

Peer comparison

Dec 31, 2023